The next question often changes the answer.
These are the questions we return to when an interesting biological story turns into a claim about people. You don't need all the technical terms to follow them. You do need to know what was tested.
Why doesn't a mechanism settle the benefit?
A mechanism explains an interaction. A benefit is something people have to measure. Those can be related, but they aren't the same observation. Knowing why a treatment might work doesn't tell us whether it did.
Ipamorelin is a useful example. Early experiments found growth hormone release, and a study in healthy men measured that signal too. The bowel-surgery trial asked a different question: could patients tolerate a meal sooner? It didn't find a convincing difference.
The signal can be real while the hoped-for outcome remains unproven. We don't have to dismiss the biology to notice that gap. It tells us which claim the evidence can carry, and which needs more work.
An explanation helps us see why a study was worth doing. The result still gets its own say.
Does a negative trial erase the biology?
No. It limits a claim about the outcome tested. The large thymosin alpha-1 sepsis trial found no clear improvement in survival at 28 days. That directly matters to claims about helping adults with sepsis, a dangerous response to infection.
The paper declared manufacturer support and financial relationships among authors. Its hospital setting matters too. It didn't test healthy people hoping to catch fewer colds, so it can't answer that question in either direction.
A disappointing result can be useful without becoming a verdict on every possible effect. The clearer question is which people, which comparison and which outcome we're talking about. That keeps the conclusion close to the test.
Reading can clarify a finding while leaving the personal care question open.
What changes when it becomes personal?
Your medical history, current problem and other treatments matter. This guide doesn't have that context and gives no medical advice. A clinician's assessment has a different job from an explanation of a study.
Approval is a separate question too. FDA explains that compounded drugs aren't FDA-approved. A prescription doesn't supply the missing approval review. It also doesn't establish a benefit that research hasn't shown.
The comparison page explains why the four peptides have different evidence histories. Each compound page keeps safety beside the mechanism. They can clarify claims; they can't choose or plan treatment for you.